Fatima Rangwala

2.8k citations

34 papers · 1.6k indexed · 1 hit paper · h-index 14

Impact in

Endocrinology, Diabetes and Metabolism top 5%
- Thyroid Cancer Diagnosis and Treatment
Oncology top 5%
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies

Papers in

Oncology 20
- Colorectal Cancer Treatments and Studies 7
- Cancer-related Molecular Pathways 5
- Cancer Treatment and Pharmacology 4
Neurology 5
- Neuroblastoma Research and Treatments 4
- Neurofibromatosis and Schwannoma Cases 4

Co-authors: Jan H.M. Schellens Vivek Subbiah Bijoyesh Mookerjee Robert J. Kreitman Zev A. Wainberg Patrick Y. Wen Bhumsuk Keam Y. Choi
Journals: Journal of Clinical Oncology (11 papers)BMC Cancer (2 papers)Annals of Oncology (2 papers)Neuro-Oncology (1 paper)The Journal of Pediatrics (1 paper)
Partner nations: United States France Netherlands

In The Last Decade

Fatima Rangwala

32 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer 2017 · 607 citations

Peers

Countries citing papers authored by Fatima Rangwala

Since Specialization

Citations

This map shows the geographic impact of Fatima Rangwala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatima Rangwala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatima Rangwala more than expected).

Fields of papers citing papers by Fatima Rangwala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatima Rangwala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatima Rangwala. The network helps show where Fatima Rangwala may publish in the future.

Co-authors

The 25 scholars most cited alongside Fatima Rangwala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fatima Rangwala Line = papers co-authored together Fatima Rangwala links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Journal of Clinical Oncology ·Laurence Albigès, Robert J. Motzer, Julia Shah, Ravindran Kanesvaran, Rosfazliszah Zahit, Melissa A. Reimers, Juan Pablo Sade, Damien Pouessel, Elisa Biscaldi, Emilio Esteban, Jóse Ángel Arranz Arija, Scott S. Tykodi, Haijun Ma, Lei Zhou, Joey Moree, Andrew D. Simmons, Fatima Rangwala, David A. Braun, Toni K. Choueiri, Thomas Powles	2025	5
2	Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma. Journal of Clinical Oncology ·Katherine I. Zhou, Maria Anna Charitopoulou, Chenyu Lin, Parra Roberto, Daniel McSkimming, Michael J. Kelley, Fatima Rangwala	2025	0
3	Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Journal of Clinical Oncology ·Robert J. Motzer, Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Camillo Porta, Cristina Suárez, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Fatima Rangwala, Margarita Askelson, 熊艳玲, A. M. Bregman, Toni K. Choueiri	2025	5
4	First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer Journal for ImmunoTherapy of Cancer ·Nehal J. Lakhani, Daphne Stewart, Debra L. Richardson, Flori Berhane, Linda Van Le, Justin Call, Fatima Rangwala, Guanfang Wang, Bo Ma, Simon Metenou, 和雄若林, Elliot Offman, Lini Pandite, Erika Hamilton	2025	5
5	429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer Regular and Young Investigator Award Abstracts ·Nehal J. Lakhani, Debra L. Richardson, Абрамова Наталья Олеговна, Fatima Rangwala, Rodolfo Nazar S, Louis Gonzalez, Bo Ma, Lini Pandite, Erika Hamilton	2021	2
6	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer BMC Cancer ·John H. Strickler, Christel Rushing, Donna Niedzwiecki, Jean-Sébastien Marsan, Ivy Altomare, Hope E. Uronis, Shiaowen David Hsu, S. Yousuf Zafar, Michael A. Morse, David Chang, James L. Wells, Kimberly Blackwell, P. Kelly Marcom, Krisada Jaewjareon, H. Kerp, J. J. Qin, Fatima Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz	2019	9
7	Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) Annals of Oncology ·Bhumsuk Keam, Robert J. Kreitman, Zev A. Wainberg, Maria E. Cabanillas, Elufimova Ei, Antoîne Italiano, Alexander Stein, Y. Choi, Jan H.M. Schellens, Patrick Y. Wen, C. C. Zielinski, Aislyn Boran, Bijoyesh Mookerjee, (unknown), Fatima Rangwala, Vivek Subbiah	2018	11
8	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer Journal of Clinical Oncology ·Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, S N Qi, Fatima Rangwala, Bhumsuk Keam Hit paper breakdown →	2017	607
9	Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology ·Ryan B. Corcoran, Thierry André, Takayuki Yoshino, Johanna C. Bendell, Chloé E. Atreya, Jan H.M. Schellens, Michel Ducreux, Autumn J. McRee, Salvatore Siena, Gary Middleton, Michael S. Gordon, Y. Humblet, Kei Muro, Élena Elez, Rona Yaeger, R. Sidhu, Matthew Squires, Savina Jaeger, Fatima Rangwala, Eric Van Cutsem	2016	36
10	X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology ·John H. Strickler, Fatima Rangwala, Christel Rushing, Donna Niedzwiecki, Ivy Altomare, Hope E. Uronis, Shiaowen David Hsu, S. Yousuf Zafar, Michael A. Morse, David Chang, James L. Wells, Kimberly Blackwell, P. Kelly Marcom, Jiayi Li, Zoie R. Meyers, Krisada Jaewjareon, Herbert I. Hurwitz	2016	1
11	Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician’s perspective Cancer Treatment Reviews ·Jeffrey Clarke, Herbert I. Hurwitz, Fatima Rangwala	2014	12
12	Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). Journal of Clinical Oncology ·Eileen M. O’Reilly, Lon Smith, Johanna C. Bendell, Fatima Rangwala, William Schmidt, Joe Stephenson, Ann M. Kapoun, Lu Xu, Vinícius Valenga, Lei Zhou, Jakob Dupont, Allen Lee Cohn	2014	9
13	Gastrointestinal symptoms in cancer patients with advanced disease Current Opinion in Supportive and Palliative Care ·Fatima Rangwala, S. Yousuf Zafar, Amy P. Abernethy	2012	14
14	Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines BMC Cancer ·Fatima Rangwala, Kevin P. Williams, M West Greenlee, Daniel Buser, Jennifer L. Allensworth, H. Kim Lyerly, Anna Mae Diehl, Michael A. Morse, Gayathri R. Devi	2012	29
15	Increased production of sonic hedgehog by ballooned hepatocytes The Journal of Pathology ·Fatima Rangwala, Cynthia D. Guy, Jiuyi Lü, Ayako Suzuki, James L. Burchette, Manal F. Abdelmalek, Wei Chen, Anna Mae Diehl	2011	145
16	Hedgehog Signaling Antagonist Promotes Regression of Both Liver Fibrosis and Hepatocellular Carcinoma in a Murine Model of Primary Liver Cancer PLoS ONE ·George Philips, Isaac S. Chan, Marzena Swiderska, Iren ORTIZ-LEAL, Cynthia D. Guy, Gamze Karaca, Cynthia A. Moylan, Talaignair N. Venkatraman, Sebastian Feuerlein, Wing‐Kin Syn, Youngmi Jung, Rafal P. Witek, Steve S. Choi, Gregory A. Michelotti, Fatima Rangwala, Elmar M. Merkle, Christopher D. Lascola, Anna Mae Diehl	2011	140
17	Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1 The Journal of Pediatrics ·Carlos E. Prada, Fatima Rangwala, Lisa J. Martin, Anne M. Lovell, Howard M. Saal, Elizabeth K. Schorry, Robert J. Hopkin	2011	115
18	Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues Cancer Research ·Shyra J. Miller, Fatima Rangwala, Jon Williams, Peter Ackerman, Sue Kong, Anil G. Jegga, Sérgio Kaiser, Bruce J. Aronow, Silke Frahm, Lan Kluwe, Victor Mautner, Meena Upadhyaya, David Muir, Margaret R. Wallace, Jussara Hagen, Dawn E. Quelle, Mark A. Watson, Arie Perry, David H. Gutmann, Nancy Ratner	2006	158
19	Malignant peripheral nerve sheath tumors with high and low Ras‐GTP are permissive for oncolytic herpes simplex virus mutants Pediatric Blood & Cancer ·Yonatan Y. Mahller, Fatima Rangwala, Nancy Ratner, Timothy P. Cripe	2005	33
20	Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells Oncogene ·Yuan Huang, Fatima Rangwala, Patricia C. Fulkerson, Bo Ling, Erin G. Reed-Geaghan, Adrienne D. Cox, John Kamholz, Nancy Ratner	2004	35

About Fatima Rangwala

Fatima Rangwala is a scholar working on Oncology, Neurology, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 34 papers that have together received 1.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Melanoma and MAPK Pathways (5 papers), Cancer-related Molecular Pathways (5 papers), Cancer Genomics and Diagnostics (4 papers), Neuroblastoma Research and Treatments (4 papers), Cancer Treatment and Pharmacology (4 papers), Neurofibromatosis and Schwannoma Cases (4 papers) and Renal cell carcinoma treatment (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (421 citations), Oncology (557 citations), Hepatology (158 citations), Neurology (282 citations) and Pathology and Forensic Medicine (260 citations). Fatima Rangwala has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include Jan H.M. Schellens, Vivek Subbiah, Bijoyesh Mookerjee, Robert J. Kreitman, Zev A. Wainberg, Patrick Y. Wen, Bhumsuk Keam, Y. Choi, Christoph Zielinski and Maria E. Cabanillas. Their work appears in journals such as Journal of Clinical Oncology, BMC Cancer, Annals of Oncology, Neuro-Oncology and The Journal of Pediatrics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact